NCT00992095已完成不适用
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Buprenorphine HCl (Sublingual) 8 mg Tablets With a Naltrexone Block Under Fasting Conditions
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 2
- 主要终点
- bioequivalence determined by statistical comparison Cmax
研究概览
简要总结
The objective of this study was to prove the bioequivalence of Buprenorphine HCl 8 mg tablet under fasted conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
排除标准
- •Positive test for HIV, Hepatitis B, or Hepatitis C.
- •Treatment with known enzyme altering drugs. History of allergic or adverse response to buprenorphine hydrochloride or any comparable or similar product.
结局指标
主要结局
bioequivalence determined by statistical comparison Cmax
时间窗: 21 days
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.OsteoarthritisNCT00315848Purdue Pharma LP225
已完成
3 期
The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.Chronic Low Back PainNCT00315887Purdue Pharma LP250
已完成
不适用
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed ConditionsEssential HypertensionNCT01013155Roxane Laboratories48
终止
1 期
Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting ConditionsDepressive DisorderNCT01046214Teva Pharmaceuticals USA8
已完成
不适用
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted ConditionsEssential HypertensionNCT01012687Roxane Laboratories48